Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Xenetic Contracts Assigned to Baxalta | Contract Pharma

What are you searching for?

Sign in
Breaking News

Xenetic Contracts Assigned to Baxalta

Exclusive R&D, license and supply pact uses Xenetic’s PolyXen technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Xenetic Biosciences’ contracts and arrangements with Baxter Healthcare SA and Baxter Healthcare Corp., have now been assigned to Baxalta Inc. as part of the spin out of the company’s biopharmaceutical business. 
 
Xenetic has an exclusive research, development, license and supply agreement with Baxalta to develop products with an extended half-life of certain proteins and molecules using its PolyXen technology. The resulting drug candidate is designed to create a longer-acting haemophilia drug, a polysialylated recombinant Factor VIII (“rFVIII”) protein, than what is currently available on the market. 
 
Baxter also has rights that extend to treatments of the failure of blood to coagulate. Baxalta expects to begin Clinical Trial Authorization (CTA, EU) and Investigational New Drug (IND, U.S.) submissions on this drug candidate in the coming months.
 
As a result of a revised license deal, Xenetic is entitled to as much as $100 million in potential development, regulatory, sales milestones, as well as royalties on sales. In connection with this deal, Baxalta also made a $10 million equity investment.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics